Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer Statistics, 2021.CA: A Cancer J Clinicians. 2021; 71: 7-33
- Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science. 1987; 235: 177-182
- Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med. 2001; 344: 783-792
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.The Lancet. 2014; 384: 164-172
- Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis.Clin Cancer Res. 2020; 26: 2838-2848
- Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial.JAMA Oncol. 2020; 6: 1355-1362
- The neoadjuvant model is still the future for drug development in breast cancer.Clin Cancer Res. 2015; 21: 2911
- Pathological complete response and accelerated drug approval in early breast cancer.N Engl J Med. 2012; 366: 2438-2441
- NCCN Clinical practice guidelines in oncology (NCCN Guidelines®): breast cancer.https://www.nccn.org/professionals/physician_gls/pdf/breast.pdfDate: 2022Date accessed: July 2, 2022
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.Lancet Oncol. 2012; 13: 25-32
- Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.Eur J Cancer. 2018; 89: 27-35
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).Ann Oncol. 2013; 24: 2278-2284
- Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2018; 19: 1630-1640
- Anthracycline-induced cardiomyopathy in adults.in: Prakash Y.S. Comprehensive physiology. John Wiley & Sons, Inc., 2011
- Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis.Breast Cancer Res Treat. 2012; 135: 335-346
- Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience.J Clin Oncol. 1995; 13: 1557-1563
- Trastuzumab emtansine for residual invasive HER2-positive breast cancer.N Engl J Med. 2019; 380: 617-628
- Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.Ann Oncol. 2021; 32: 1005-1014
- Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE.Ann Oncol. 2020; 31: S48-S53
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.N Engl J Med. 2017; 377: 122-131
- Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.Clin Breast Cancer. 2021; 21: 80-91 e87
- Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.Ann Oncol. 2020; 31: 1223-1230
- High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.J Clin Oncol. 2009; 27: 5700-5706
- Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.J Clin Oncol. 2008; 26: 5697-5704
- Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.J Clin Oncol. 2014; 32: 2142-2150
- US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.J Natl Cancer Inst. 2014; 106
- Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.J Clin Oncol. 2019; 37: 1868-1875
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.J Clin Oncol. 2021; 39: 2375-2385
- Cancer Treatment Adaptations in the COVID-19 Era.JCO Oncol Pract. 2020; 16: 305-307
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.N Engl J Med. 2005; 353: 1673-1684
- Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.N Engl J Med. 2005; 353: 1659-1672
- Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-> T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-> TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study.Breast Cancer Res Treat. 2005; 94: S5
- Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study.Ann Oncol. 2018; 29: 2328-2333
- Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2–positive breast cancer: the SOLD randomized clinical trial.JAMA Oncol. 2018; 4: 1199-1206
- 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.Lancet. 2019; 393: 2591-2598
- 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.Lancet. 2019; 393: 2599-2612
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer.N Engl J Med. 2015; 372: 724-734
- Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.J Clin Oncol. 2009; 27: 5538-5546
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study.J Clin Oncol. 2009; 27: 5529-5537
- Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: updated results of ALTERNATIVE.J Clin Oncol. 2021; 39: 79-89
- First-Line Trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2–positive and hormone receptor–positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial.J Clin Oncol. 2018; 36: 2826-2835
- Trastuzumab Plus endocrine therapy or chemotherapy as first-line treatment for patients with hormone receptor–positive and HER2-positive metastatic breast cancer (SYSUCC-002).Clin Cancer Res. 2021; 28: 637-645
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer.N Engl J Med. 2012; 367: 1783-1791
- Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.Cancer Sci. 2016; 107: 1039-1046
- Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-Low–expressing advanced breast cancer: results from a phase Ib study.J Clin Oncol. 2020; 38: 1887-1896
- Trastuzumab deruxtecan in previously treated HER2-positive breast cancer.N Engl J Med. 2020; 382: 610-621
- Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer.N Engl J Med. 2022; 386: 1143-1154
- 92O - Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd).Ann Oncol. 2021; 32: S60-S78
- Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management.Cancer Treat Rev. 2022; 106: 102378
- In Vivo Activity of ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2 in Combination with Trastuzumab, Docetaxel or Bevacizumab.Cancer Res. 2009; 69: 5104
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.N Engl J Med. 2019; 382: 597-609
- Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial.J Clin Oncol. 2020; 38: 3138-3149
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer.N Engl J Med. 2006; 355: 2733-2743
- Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.JAMA Oncol. 2021; 7: 573-584
- Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis.Cancer Res. 2022; 82 (PD8-01-PD08-01)
- Abstract P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study.Cancer Res. 2022; 82 (P2-13-07-P12-13-07)
- Novel development strategies and challenges for anti-Her2 antibody-drug conjugates.Antib Ther. 2022; 5: 18-29
- Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.Lancet Oncol. 2020; 21: 763-775
- Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.Lancet Oncol. 2020; 21: 1283-1295
- Cardiac surveillance for anti-HER2 chemotherapy.Cleve Clin J Med. 2021; 88: 110-116
- Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.J Clin Oncol. 2007; 25: 3859-3865
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
